- Home
- EBS
as 06-30-2025 3:31pm EST
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | GAITHERSBURG |
| Market Cap: | 337.6M | IPO Year: | 2006 |
| Target Price: | $14.33 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.02 - $15.10 | Next Earning Date: | 08-05-2025 |
| Revenue: | $965,400,000 | Revenue Growth: | -18.56% |
| Revenue Growth (this year): | -22.58% | Revenue Growth (next year): | 18.88% |
Stock Insider Trading Activity of Emergent Biosolutions Inc. (EBS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Katkin Keith | EBS | Director | May 23 '25 | Sell | $6.30 | 7,844 | $49,417.20 | 86,431 | |
| PAPA JOSEPH C | EBS | President and CEO | May 13 '25 | Buy | $5.83 | 60,000 | $349,800.00 | 342,500 |
Latest Emergent Biosolutions Inc. News
EBS Breaking Stock News: Dive into EBS Ticker-Specific Updates for Smart Investing
MT Newswires
7 days ago
Emergent BioSolutions Awarded $62.4 Million Contract Modification for Botulism Antitoxin Supply
![Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply](https://cdn.finquota.com/news/4f3fe4a2-7bfb-44d5-8bb2-4caf35e54a87.png)
GlobeNewswire
7 days ago
Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply
MT Newswires
10 days ago
Emergent BioSolutions to Join Russell 3000 Index; Shares Up Pre-Bell
GlobeNewswire
10 days ago
Emergent BioSolutions Announces Addition to Russell 3000® Index
GlobeNewswire
25 days ago
Emergent BioSolutions Supports Victoria's Voice Foundation’s National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies
Zacks
a month ago
5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost
Zacks
a month ago
Zacks.com featured highlights include BrightSpring Health Services, Beyond, Air Canada, HF Sinclair and Emergent BioSolutions
Zacks
a month ago
5 Broker-Loved Stocks to Watch Amid Signs of Easing Trade Woes
Compare EBS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EBS Emergent Biosolutions Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.